{"url_path":"/sec/oprx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1448431/0001448431-26-000011-index.html","accession_number":"0001448431-26-000011","cik":"0001448431","ticker":"OPRX","issuer_name":"OptimizeRx Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1448431/0001448431-26-000011-index.html","primary_entity_key":"0001448431","primary_entity_name":"OptimizeRx Corp"},"word_count":350,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nExhibit NumberDescription of Exhibit\n\n3.1\n[Articles of Incorporation of OptimizeRx Corporation (the “Company”) Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (Registration No. 333-155280) filed on November 12, 2008.](https://www.sec.gov/Archives/edgar/data/1448431/000136110608000414/optimizerx_s1-ex0301.htm)\n\n3.2\n[Certificate of Correction, dated April 30, 2018. Incorporated by reference to Exhibit 3.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.](https://www.sec.gov/Archives/edgar/data/1448431/000121390019003962/f10k2018ex3-5_optimizerx.htm)\n\n3.3\n[Fourth Amended and Restated Bylaws of the Company. Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.](https://www.sec.gov/Archives/edgar/data/1448431/000144843125000012/fourthamendedrestatedbylaws.htm)\n\n10.1\n[Amendment No. 4 to Financing Agreement, dated March 2, 2026. Incorporated by reference to Exhibit 3.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.](https://www.sec.gov/Archives/edgar/data/1448431/000144843126000005/ex1024amendmentno4.htm)\n\n31.1**\n[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](oprx-20260331xex311.htm)\n\n31.2**\n[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](oprx-20260331xex312.htm)\n\n32.1**\n[Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](oprx-20260331xex321.htm)\n\n101.INS**Inline XBRL Instance Document\n\n101.SCHInline XBRL Taxonomy Extension Schema Document\n\n101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LABInline XBRL Taxonomy Extension Label Linkbase Document\n\n104**Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n* Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request.\n\n** Filed or furnished herewith.\n\n29\n\n[Table of Contents](#i676fe0a0881d4aa987d10830578e4845_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nOptimizeRx Corporation\n\nDate: May 13, 2026\n\nBy:/s/ Stephen Silvestro\n\nStephen Silvestro\n\nTitle: Chief Executive Officer\n\nOptimizeRx Corporation\n\nDate: May 13, 2026\n\nBy:/s/ Edward Stelmakh\n\nEdward Stelmakh\n\nTitle: Chief Financial & Strategy Officer\n\n30"}